AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04226768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Haematology Palliative Care (Fast-track) Group
Description: Early and proactive multidisciplinary care
Study NCT04226768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Conventional care and referral as indicated
Study NCT01470170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted controlled infusion
Description: The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model
Study NCT01470170 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Targeted controlled infusion
Description: The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model
Study NCT01470170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
Study NCT01470170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
Study NCT05066490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: Treadmill training at moderate intensity.
Study NCT05066490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exersises.
Description: Resistance exercises using the 10 repetition maximum.
Study NCT02911428 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling collection
Description: It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
Study NCT03396380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D with calcium and clomiphene citrate
Description: 1. Vitamin D ( ossofortin®, EVA PHARMA) 10000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. Induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily) starting from the third day of menstrual cycle and for five days .
Study NCT03396380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet with calcium and clomiphene citrate
Description: 1. The placebo tablet twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily)starting from the 3rd day of menstrual cycle and for five days
Study NCT04608695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian puncture
Description: One side ovary of each patient included in the study, will be punctured 10 times under trans-vaginal ultrasound guidance with 17 gauge ovarian pick up needle, 1 month before the scheduled IVF cycle. Control group will be the other side ovary for each patient. Number of ≥ 14 mm follicle and collected oocytes will be compared.
Study NCT02841371 — intervention group
Intervention type: RADIATION
Intervention: 99mTc-DTPA
Description: a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
Study NCT02780882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Study NCT05223361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxy ethyl starch 130/0.4
Description: 6% HES 130/0.4 additive to ringer lactate as prime solution
Study NCT05223361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Ringer lactate as prime solution
Study NCT01478854 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.
Study NCT01478854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Temozolomide
Study NCT00502190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicon ring positioned in the vagina, around the cervix
Description: Silicon ring positioned in the vagina, around the cervix
Study NCT02059590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridinylmethyl-14C-labeled isavuconazonium sulfate
Description: Intravenous
Study NCT03891901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tablets, administered orally
Study NCT03891901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300 mg tablets, administered orally
Study NCT03891901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg capsules, administered orally
Study NCT01182831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous fluoro guided celiac plexus neurolysis
Description: It is percutaneous injection of neurolytic agent in and around the celiac ganglion
Study NCT01182831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS guided neurolysis
Description: It is injection of neurolytic agent in and around the celiac ganglion using an echo endoscope.
Study NCT01069497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention of infections program
Description: The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:~* a slide-show of recommendations (commented by an expert),~* recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec.
Study NCT03400800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran Sodium
Description: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
Study NCT03400800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study NCT01698528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet Computer
Study NCT02868346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anal swab
Study NCT04340973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes
Study NCT04340973 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes
Study NCT01757548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open operation
Description: high ligation of spermatic vein by open operation
Study NCT01757548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microsurgery
Description: high ligation of spermatic vein by microsurgery
Study NCT01425112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Description: Surgery for complications of trabeculectomy
Study NCT01947933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirikizumab- IV
Description: Administered IV
Study NCT01947933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirikizumab - SC
Description: Administered SC
Study NCT01947933 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV
Study NCT02991521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast exam
Description: Positional change before Fast exam
Study NCT03948945 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Profile HaloTM Mixed Fractional Laser
Description: Profile HaloTM fractional laser is the world's first hand tool with nonablative and ablative fractional laser. It includes a nonablative fractional laser with a wavelength of 1470 nm and an ablative fractional laser with a wavelength of 2940 nm. It has a good therapeutic effect on skin aging.
Study NCT01379144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost 75 ug
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Study NCT01379144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost 100 ug
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.
Study NCT01373619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: ivabradine titrated to 7.5 mg BID
Study NCT06023797 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant immunochemotherapy
Description: Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.
Study NCT03040531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Genistein aglycone
Description: 27mg bid in tablets
Study NCT03040531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate Oral Tablet
Description: 70 mg/week in tablets
Study NCT03040531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium + vitamin D3 tablet
Description: 500mg Calcium + 200 IU Vitamin D3 bid in tablets
Study NCT02096913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolormin® extra (Ibuprofen)
Description: Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period.
Study NCT02096913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolormin® extra (Ibuprofen)
Description: Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment.
Study NCT00564239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy
Description: 12 children group sessions, 8 parent group sessions
Study NCT00564239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy
Description: 12 children group sessions
Study NCT02741778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally invasive group
Description: In this group, all manipulations are finished by laparoscopy and thoracoscopy.
Study NCT02741778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open group
Description: Right lateral position, Traditional thoracotomy through the 7th intercostal incision.
Study NCT01498549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: Atomoxetine 40mg and 80mg compared to the sugar pill
Study NCT01498549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill compared to Atomoxetine 40mg and 80mg.
Study NCT03188198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim
Study NCT03188198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim
Study NCT02238366 — intervention group
Intervention type: DRUG
Intervention: triptorelin
Description: This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
Study NCT01243281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-IFN and entecavir
Description: The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
Study NCT03641157 — intervention group
Intervention type: OTHER
Intervention: Easy Intubation
Study NCT00944554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline given twice a day or five weeks.
Study NCT00944554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given twice a day or five weeks.
Study NCT00894192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Izon Wavefront-guided lenses
Description: Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
Study NCT00894192 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional lenses
Description: We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
Study NCT03452787 — intervention group
Intervention type: OTHER
Intervention: None, cohort studies
Description: this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.
Study NCT01939457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT00080626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg injection on day 1 of each cycle
Study NCT00080626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 100 mg per meter-squared, every 14 days for 4 cycles
Study NCT00080626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: lumpectomy or mastectomy at end of treatment
Study NCT00080626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: treatment prior to definitive breast surgery
Study NCT00658528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
Study NCT00658528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
Study NCT03834090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rESWT
Description: rESWT was administered once per week for 3 weeks using a ShockMaster 500 device with 1.8 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses.
Study NCT03834090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercises
Description: A program including post-isometric relaxation, and progressive resistance exercise (eccentric wrist extension) on the wrist extensors
Study NCT03665545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMA950/Poly-ICLC
Description: IMA950 mixed with Poly-ICLC administered subcutaneously
Study NCT03665545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA950/Poly-ICLC
Description: IMA950 mixed with Poly-ICLC administered subcutaneously
Study NCT03665545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA950/Poly-ICLC and pembrolizumab
Description: IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
Study NCT02479282 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: natural cesarean section
Study NCT02479282 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: traditional cesarean section
Study NCT03290768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
Study NCT03290768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Tracker
Description: Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
Study NCT03290768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
Study NCT03153657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam-Beta-Cyclodextrin
Description: The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
Study NCT03153657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Piroxicam-Beta-Cyclodextrin
Description: The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
Study NCT03153657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
Study NCT03153657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
Study NCT02332759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Materna Medical
Study NCT03491410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Low Dose
Description: Low-Dose Aspirin is to be added in the standard patient´s treatment
Study NCT03491410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo is to be added in the standard patient´s treatment
Study NCT04002544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NTG patch
Description: A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half
Study NCT04002544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gauze cover
Description: A gauze will be applied near the radial artery pulsation to ensure blinding
Study NCT04002544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gauze cover
Description: A gauze will be applied near the radial artery pulsation to ensure blinding
Study NCT02989935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation
Description: Measurements of ventilation with subjects seated, and breathing across a pneumotachygraph and pressure transducer to measure inspiratory airflow, during both resting and CO2 stimulated breathing.
Study NCT02989935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parasternal EMG
Description: Recordings of electrical activity (EMG) from the parasternal intercostal muscle in the second intercostal space on the upper anterior chest wall adjacent to the sternum.